iSpecimen Launches Marketplace Onsite Program to Optimize Biospecimen Procurement Process for Sample Providers
iSpecimen (Nasdaq: ISPC) has launched its Marketplace Onsite program to enhance support for biospecimen provider partners. By embedding coordinators at select partner sites, the program streamlines the fulfillment of sample and data requests, thereby reducing strain on staff. The initiative aims to expand the provider network, increase access to high-demand biospecimens, and improve revenue growth. Interim CEO Tracy Curley emphasized the program's potential to address supplier constraints and facilitate vital medical research.
- Launch of Marketplace Onsite program aims to streamline request fulfillment and support biospecimen provider partners.
- Program enhances accessibility to high-demand biospecimens for researchers, potentially driving revenue growth.
- Interim CEO's statement indicates focus on addressing supplier constraints and expanding the provider network.
- None.
New Program Designed to Support Provider Partners with Onsite Coordinator
LEXINGTON, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today launched its new Marketplace Onsite program to offer additional support to the Company’s biospecimen provider partners. The program embeds a coordinator at select partner sites to facilitate fulfillment of incoming sample and data requests from the proprietary iSpecimen Marketplace® platform. With this extra layer of support, iSpecimen and its partners will be able to expand and streamline access to biospecimens for research.
The Marketplace Onsite coordinator will field all requests and submit proposals on behalf of the provider, streamlining sample-related management and reducing strain on existing staff and product pipelines. The Marketplace Onsite program will also help with building and contracting with a network of researchers, providing remuneration for biospecimens and data, offering IT assistance for data management needs and covering the expenses of the iSpecimen Onsite employee.
“The Marketplace Onsite program is the first of many internal initiatives focused on addressing our supplier constraints, which will allow us to grow our revenue further,” said Tracy Curley, interim CEO, iSpecimen. “This initiative aims to further support and expand our provider network while increasing access to biospecimens that are in high-demand or traditionally harder to find. We remain steadfast in our mission to connect scientists with healthcare providers that have access to patients and biospecimens needed for key medical advancements.”
About iSpecimen Marketplace
The iSpecimen Marketplace is a novel technology platform that connects life sciences researchers who need biospecimens for their research with patients and healthcare organizations that can provide these samples. The Marketplace specifically addresses procurement inefficiencies that have traditionally forced researchers to limit the scope of their work due to the shortage of quality biospecimens. Researchers can search for biospecimens based on demographic traits, medical conditions, procedures, blood type, country of collection and much more.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss
iSpecimen@kcsa.com
Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com
FAQ
What is the purpose of iSpecimen's Marketplace Onsite program?
How does the Marketplace Onsite program affect sample management?
What is iSpecimen's focus with the new Marketplace Onsite initiative?
Who is the interim CEO of iSpecimen?
What stock symbol is associated with iSpecimen?
